30.06.2008 12:01:00
|
FDA Approves First and Only Single-Dose Antibiotic for Dogs and Cats
Pfizer Animal Health has announced the Food and Drug Administration
(FDA) has approved Convenia® (cefovecin
sodium), the first and only antibiotic for dogs and cats available in a
single veterinarian-administered injectable dose.
Convenia provides up to 14 days of antibiotic treatment in a single dose
for the most common skin infections in dogs and cats –
the No. 1 reason pets are prescribed antibiotics.1
By relieving pet owners of the often impractical responsibility of
giving pills to their pets several times a day for weeks at a time,
Convenia ensures the antibiotic course of treatment is completed on
time, giving the pet the best chance for treatment success.
"We understand how difficult it can be for
owners to give their pets the right pills at the right time. With career
and family responsibilities, many people simply aren’t
around at appropriate intervals once, twice or even more times a day
despite their best intentions,” said George
Fennell, vice president, Companion Animal Division, Pfizer Animal
Health. "With Convenia, the pet gets the dose
it needs right in the veterinarian’s office –
so owners don’t have to worry about when and
how to give pills to their pets.”
The third in a string of new companion animal products in 15 months –
following the approvals of the first canine obesity medication and the
first veterinary drug to control vomiting in dogs, both in early 2007 –
Convenia represents yet another first from Pfizer Animal Health.
Convenia is now available at veterinary practices nationwide.
‘Pilling’ is a
Challenging Responsibility for Pet Owners
Antibiotics currently in use for dogs and cats, while generally
effective, can be challenging for owners to give due to the need for
daily or twice daily oral doses over several weeks. Besides busy
lifestyles that often don’t allow owners to
be physically present to give their pets oral medications at the right
times, owners often forget to give pills and they prematurely end
therapy when their pets start to look or act better.
Some pet owners report that pets resist "pilling”
or other orally administered medications. Research shows that 30 percent
of dog owners have trouble pilling their dogs, while cat owners rank
pilling as one of the most stressful activities involved with caring for
their cats.2
When doses are not given on time or when they are missed or stopped
prematurely, pets do not receive optimal treatment and risk treatment
failure, deterioration of health, and additional veterinary visits.
Veterinarians report that non-compliance is the major cause of treatment
failures and/or relapses in antibiotic therapy.3 "The approval of Convenia, the first in its
class, marks a significant milestone in the effective administration of
antibiotics for companion animals,” said Amy
Trettien, DVM, Pfizer Animal Health. "For the
first time, we may be able to see what 100 percent antibiotic compliance
looks like.” Full Course of Antibiotic Treatment
Skin infections, which are caused by a variety of bacterial pathogens,
are the No. 1 reason dogs and cats receive antibiotic treatment.1
In dogs, skin infections are typically a response to an allergy or
parasite infestations that result in scratching, licking and biting
behavior that can weaken skin and make it susceptible to bacterial
infections. In cats, skin infections are typically in response to wounds
or bites that become infected.
In U.S. clinical trials with 26 veterinary clinics, Convenia was proven
to be statistically equivalent to a 14-day course of antibiotics with a
veterinary-labeled, multi-day oral cephalosporin antibiotic. Study
results showed that, in most cases, a single dose of Convenia was
effective against naturally occurring skin infections in dogs and cats.
Treatment outcomes for both dogs and cats were as effective as the oral
antibiotic used in the study. In most cases, only a single injection was
necessary. Only 14 percent of treated canines required a second dose of
Convenia to complete treatment.
Convenia is well tolerated, and its safety has been demonstrated in
adult dogs and cats as well as in puppies and kittens. The most common
side effects seen with Convenia are similar to those seen with other
antibiotics, vomiting, diarrhea, decreased appetite and lethargy. More
than 4 million doses of Convenia have been administered to pets globally
since 2006.
For full prescribing information about Convenia, visit www.convenia.com.
About Pfizer Animal Health
Pfizer Inc (NYSE: PFE), the world’s largest
research-based pharmaceutical company, also is a world leader in
discovering and developing innovative animal vaccines and prescription
medicines. Pfizer Animal Health is dedicated to helping companion
animals live longer and healthier lives and to the safety and
productivity of the world’s food supply by
enhancing the health of livestock and poultry. For additional
information on Pfizer’s portfolio of animal
health products, go to www.PfizerAH.com.
1 Confidential PAH Market Research/2003/*US
Diary Study Wave 1, 2, 3, 4 and 5 and MDI data
2 Convenia Pilling Study, Jan. 2008 by Forward
Research
3 Pfizer Animal Health Market Research, 2005
SKIN INFECTIONS IN DOGS AND CATS FACT SHEET
How common are skin infections in
dogs and cats?
Skin infections are the No. 1 reason pets are prescribed
antibiotics.¹ Common skin infections
include pyoderma (literally, "pus in
the skin”), wounds and abscesses. For
cats, abscesses and wounds are more common.
What are the causes of skin
infections?
Skin infections are caused by a variety of bacterial pathogens,
the most common being Staphylococcus intermedius. In dogs,
skin infections typically occur in association with an allergy or
parasite infestation that causes the animal to scratch, lick, and
bite the affected area. This reaction can weaken the skin and
disrupt the skin’s natural defense
mechanisms, making it susceptible to bacterial infections. In
cats, skin infections more commonly occur after the animal
sustains a trauma or bite.
Pyodermas in dogs are classified by the depth of the infection.
Superficial pyodermas affect the top layers of skin, while deep
pyodermas involve the deeper layers of skin, and commonly extend
beneath the hair follicle.
Less commonly, skin infections may be secondary to a hormonal
disease, such as Cushing’s disease or
hypothyroidism, or other diseases that suppress the immune system.
How can you spot skin infections?
Since skin infections are generally secondary to underlying skin
problems including allergies and parasite infections, pet owners
may first notice certain behaviors that indicate a problem. For
dogs that might include biting or chewing areas like the top of
the tail or legs; closer examination might reveal broken hairs, a
rash-like appearance, red pustules and patches of thickened skin
that may look darker than the surrounding skin. Cats will
sometimes appear to be itchy, especially around their head and
ears, and scratch these areas.
How are skin infections treated?
Skin infections in both dogs and cats are generally treated with
systemic antibiotics. For superficial infections, antibiotics are
generally administered for 14-21 days. For deeper, more severe
infections, treatment can last eight weeks or even longer.
Along with oral antibiotics, veterinarians may also recommend an
antiseptic shampoo and if the primary disease that led to skin
infection can be determined (for example, allergies or a parasite
infection like fleas), treatment of the underlying problem.
Are skin infections difficult to
treat?
While antibiotics currently used to treat skin infections in dogs
and cats are generally effective, treatment can prove difficult
for some owners, generally because the treatment is administered
at home over a long period of time. Some common challenges include:
Scheduling: Antibiotic therapies usually require dosing at
regular intervals over an extended period of time, generally
twice a day at 12-hour intervals. Some owners, due to scheduling
issues and other demands on time, occasionally have difficulty
administering the correct dose in the proper timeframe,
especially when the treatment period is of long duration.
Stopping therapy too soon: Some owners, once their pet begins to
heal, stop treatment early, or skip or forget to administer the
antibiotic. This can lead to less than optimal treatment, and
put the pet at risk of treatment failure. Skin infections,
although sometimes appearing to be cured, can persist under the
skin or in small pockets that might not be easily seen by the
owner.
Pilling: Most antibiotics in the market are administered orally,
which can prove stressful and challenging with some pets.
Research indicates that 30 percent of dog owners have trouble
pilling their pets, while cat owners rank pilling as one of the
most stressful activities involved with caring for their cats.2
What are the long-term implications
for skin infections?
Untreated skin infections can adversely effect a pet’s
quality of life and often, the relationship between owner and pet.
Non-compliance with antibiotic treatment can contribute to a
failure to cure the condition, a prolonged disease process,
recurring infection, deteriorating health, and the need for
additional visits to the veterinarian.
1Confidential PAH Market
Research/2003/*US Diary Study Wave 1, 2, 3, 4 and 5 and MDI data
2Pfizer Animal Health Market
Research, 2005
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Pfizer Inc.mehr Nachrichten
Analysen zu Pfizer Inc.mehr Analysen
14.11.24 | Pfizer Neutral | UBS AG | |
01.11.24 | Pfizer Neutral | UBS AG | |
30.10.24 | Pfizer Buy | Goldman Sachs Group Inc. | |
29.10.24 | Pfizer Buy | Jefferies & Company Inc. | |
24.10.24 | Pfizer Neutral | JP Morgan Chase & Co. |
Aktien in diesem Artikel
Pfizer Inc. | 24,57 | 0,74% |
Indizes in diesem Artikel
Dow Jones | 44 722,06 | -0,31% | |
S&P 500 | 5 998,74 | -0,38% | |
S&P 100 | 2 883,15 | -0,41% | |
NYSE US 100 | 17 376,20 | -0,02% |